Pfizer has more than doubled the 2021 sales forecast for its Covid-19 vaccine since February and predicted another bumper year in 2022 as it expands global distribution and begins shipping jabs for boosters and children.
The US company said on Tuesday that it expected to generate $36bn in sales this year and $29bn in 2022, underlining how the vaccine developed with German partner BioNTech is dominating the global market and transforming the company’s finances.
The group, which shares profits on sales of the Covid shot evenly with BioNTech, generated direct sales of $13bn in the third quarter. Analysts had forecast Covid vaccine revenues of just under $11bn on average, according to a poll by Refinitiv.
您已阅读26%（712字），剩余74%（2059字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。